Consistent with their extraordinary vulnerability in low glucose conditions, KRAS- and BRAF-mutant CRC cells were significantly more sensitive to GLUT1 blockade compared to cells with WT KRAS and BRAF (Table 2). The gene discussed is KRAS; the disease is colorectal carcinoma.